Agilent Unveils Commercial Human CpG Island Microarray

Wednesday, September 20, 2006 Print

Agilent Technologies Inc. has introduced the commercial CpG Island microarrays for studying DNA methylation, an epigenetic modification known to play a significant role in many important cellular processes.

The term "CpG" stands for the nucleic acids cytosine and guanine with a phosphodiester bond between them.

Recently, microarrays have evolved as an analysis tool for genome-wide measurement of DNA methylation changes.

"Agilent’s high-quality oligonucleotide microarray manufacturing, custom design capability and integration with our existing assay workflow have enabled us to quickly advance our DNA methylation work," said Professor Tim Hui-Ming Huang, Department of Molecular Virology, Immunology and Medical Genetics at The Ohio State University. 

Jean-Pierre Issa, MD, professor of leukemia and director of The Translational Research Laboratories in the Leukemia Department at MD Anderson Cancer Center, uses Agilent oligo tiling microarrays to study the biology and prognostic significance of genome-wide methylation changes in cancer.

Agilent offers a human CpG island microarray and plans to add other organisms in coming months.

Researchers can also access Agilent’s database of approximately 13 million ChIP-on-chip probes through eArray v4.5, Agilent’s online design tool that enables researchers to create custom methylation designs of interest.

"For some time now, Agilent has been working closely with academic researchers to develop and optimize microarray-based methods for measuring DNA methylation," said Chris Hopkins, senior scientist, Agilent Life Sciences and Chemical Analysis.

"The 244k CpG island microarray enables these researchers to study the genomic regions most likely targeted for DNA methylation."